Same-day CAR-T production is established and refined through the comparison of novel vector and gene-editing strategies with classical methods. Both processes are then standardized to ensure consistent, clinical-scale use. It develops cutting-edge analytical assays - leveraging CRISPR off-target profiling, 3D ex vivo efficacy screens, and cytokine-release monitoring - to qualify edited cells for safety and potency. Finally, it conducts paired comparisons of the new rapid workflow versus traditional ex vivo culture to demonstrate equivalence or superiority in product quality.
Ulf is a co‑founder and CEO of T‑CURX, with more than 20 years of experience in founding, building, and successfully exiting biotechnology companies. Prior to T‑CURX, he co‑founded 4‑Antibody AG and NBE‑Therapeutics, both of which were acquired by international pharma companies, and led the companies as CEO through significant venture financings and major commercial transactions. Ulf holds a PhD in Biochemistry and has an extensive background in immunology, with over 40 peer‑reviewed publications and multiple granted and pending patents.
Jan van den Brulle serves as VP External Research & Development at T‑CURX and brings more than 20 years of experience in research and development across multiple biotechnology companies. Prior to joining T‑CURX, he held senior leadership roles at MorphoSys AG and Sloning Biotechnology, where he led large research teams, managed global pharma collaborations, and advanced multiple therapeutic antibody programs to lead candidate stage. Jan has a strong background in synthetic biology and is an inventor on numerous granted patents in the field.
Paulina is a CAR T enthusiast with a strong scientific foundation in CAR T research and hemato-oncology paired with commercialization experience, leading medical strategy towards launch of two CAR T cell therapies at BMS Germany. As Director Business Development and Program Management at T-CURX her ambition is to advance the mission to democratize CAR T therapies to reach more patients.
